Sanofi/Regeneron’s Esophagitis Data Add To Dupixent’s Winning Streak

 
• By Alaric DeArment

The companies announced positive Phase III data for the drug in patients with eosinophilic esophagitis and plan to take the results to regulators in 2022.

Sanofi and Regeneron announced results from a Phase III trial of Dupixent in eosinophilic esophagitis • Source: Shutterstock

More from Alimentary/Metabolic

More from Therapy Areas